Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Exterol returned no results
Showing 31 to 45 of 751 results for external

  1. Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]

    In development [GID-TA10893] Expected publication date: 31 July 2024

  2. The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (MTG21)

    Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury.

  3. Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome

    In development [GID-DG10074] Expected publication date: 11 September 2024

  4. Intrabeam radiotherapy system for adjuvant treatment of early breast cancer . Patient decision aid on intrabeam radiotherapy for treating early breast cancer

    local recurrence). The well-established way to do this in the NHS is by external radiotherapy. In this type of radiotherapy, radiation...

  5. Breast cancer guidelines

    breast-conserving surgery Radiotherapy after mastectomy Dose fractionation for external beam radiotherapy Familial breast cancer:...

  6. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

    Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic

  7. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (DG5)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver

  8. Odevixibat for treating progressive familial intrahepatic cholestasis (HST17)

    Evidence-based recommendations on odevixibat (Bylvay) for treating progressive familial intrahepatic cholestasis in people 6 months and older.

  9. Transient loss of consciousness ('blackouts') in over 16s (CG109)

    This guideline covers assessment, diagnosis and referral for people over 16 who have had a transient loss of consciousness (TLoC; also called a blackout). It aims to improve care for people with TLoC by specifying the most effective assessments and recommending when to refer to a specialist.

  10. SecurAcath for securing percutaneous catheters (MTG34)

    Evidence-based recommendations on SecurAcath for securing percutaneous catheters.

  11. Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)

    Evidence summaries: unlicensed and off-label medicines – Interim process statement

  12. Hearing loss in adults: assessment and management (NG98)

    This guideline covers some aspects of assessing and managing hearing loss in primary, community and secondary care. It aims to improve the quality of life for adults with hearing loss by advising healthcare staff on assessing hearing difficulties, managing earwax and referring people for audiological or specialist assessment and management.

  13. Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]

    In development [GID-HST10055] Expected publication date: 29 January 2025

  14. Avapritinib for treating advanced systemic mastocytosis ID3770

    In development [GID-TA11382] Expected publication date: TBC

  15. Social, emotional and mental wellbeing in primary and secondary education (NG223)

    This guideline covers ways to support social, emotional and mental wellbeing in children and young people in primary and secondary education (key stages 1 to 5), and people 25 years and under with special educational needs or disability in further education colleges. It aims to promote good social, emotional and psychological health to protect children and young people against behavioural and health problems.